Abdul Mannan: Managing Bleeding in Acquired Haemophilia A – Choosing the Right Haemostatic Strategy
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“In acquired haemophilia A, the best haemostatic agent depends on the patient in front of you.
Acquired haemophilia A is not the moment to admire a prolonged APTT from a distance.
If the patient is bleeding, act early and involve a haemophilia centre.
The new BSH/UKHCDO guideline keeps the message practical:
- Control bleeding first
- Avoid trauma and procedures where possible
- Use rFVIIa, aPCC/FEIBA, or rpFVIII for bleeding patients
- Monitor bypassing agents clinically, not by routine clotting tests
- Use rpFVIII when FVIII measurement can guide treatment
- Start inhibitor eradication with immunosuppression, tailored to risk
The key point?
BSH does not crown one universal winner between FEIBA, rFVIIa, and rpFVIII.
The right choice depends on the bleed, thrombotic risk, anti-porcine FVIII inhibitor status, lab support, access, and local haemophilia centre practice.
FEIBA/aPCC and rFVIIa remain trusted bypassing options. rpFVIII has the practical advantage of measurable FVIII levels, which can be very helpful when the bleeding is severe or the response is unclear.
AHA is rare, but when it appears, it tends to theatre. The platelet count sits there innocently while the APTT does all the shouting.
What drives your first choice in AHA bleeding: thrombosis risk, lab monitoring, local access, or centre protocol?”
Find more posts from Abdul Mannan on Hemostasis Today.
-
May 30, 2026, 14:36Mona Ranade: Joining Experts to Advance Acute Pulmonary Embolism Care at the PE Virtual Connection Forum
-
May 30, 2026, 14:25Rena D. Sukhdeo Singh: Celebrating the Launch of Stroke Smart West Virginia
-
May 30, 2026, 14:11Monica Verduzco-Gutierrez: A New Spasticity Education and Patient Journey Resource for Stroke Awareness Month Is Now Live
-
May 30, 2026, 13:59Chinua Onyebuchi: Proud to Contribute to The Wider Mission of The British Heart Foundation and The Stroke Association
-
May 30, 2026, 13:52Gerrit M. Grosse: How Integrative Biomarker Approaches May Improve Our Understanding of Brain-Immune Crosstalk After Stroke
-
May 30, 2026, 13:15Highlight Groundbreaking and Emerging Science From the Posters by Leading an ASH Poster Walk at ASH26
-
May 30, 2026, 10:36Saman Adnan: New Research Explores Readmission Risk in Brain Cancer Patients With VTE
-
May 30, 2026, 10:27Sartaj Alam: CBC Analyzer – The Backbone of Modern Hematology Diagnostics
-
May 30, 2026, 10:17Factor X Deficiency – From Mild Bruising to Life Threatening Hemorrhage – ICHCC